Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rx SEDATIVE CONTRACEPTIVE AND DIURETIC PRICES

Executive Summary

Rx SEDATIVE CONTRACEPTIVE AND DIURETIC PRICES remained flat during the four-month period ended June 30, according to just-released Producer Price lndex data from the Labor Dept.'s Bureau of Labor Statistics. The bureau's figures, released July 12, indicate that from February through June contraceptive and sedative prices remained unchanged. Prices for diuretics edged up 0.2%. The contraceptive category has shown no increase through the first six months of 1985, while diuretics are up 4.2%. The sedative group, however, has increased 17.4% since the beginning of the year. Overall ethical drug prices are increasing at about a 9% annual pace. Through six months the index is up 4.5%. The pharmaceutical figures are still running well ahead of the index for finished goods, which is up only 0.5% through June. Ethicals with the largest growth for the four month period include bronchial therapy products, which jumped 10.3%, and central nervous system stimulants, which increased 8.9%.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

OM017301

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel